Why the study?
Systemic inflammation is a major cardiovascular risk factor in patients undergoing TAVR but is not adequately portrayed in pre-interventional risk assessment scores.
Do elevated plasma levels of TNF-α predict 12-month mortality in patients undergoing TAVR?
Cohort (n=431)
Do elevated plasma levels of TNF-α predict 12-month mortality in patients undergoing TAVR?
Hazard Ratio: 1.003 (95% CI 1.001–1.005)
Absolute Event Rate: 18.8% vs 2.8%
p-value: p=0.013
Elevated plasma TNF-α levels at 24 hours and 5 days post-TAVR are independently associated with increased 12-month mortality, highlighting its potential as a prognostic biomarker.
No takes yet. Share an insight, caveat, or question.
Mirna et al. (2021) conducted a cohort in Transfemoral transcatheter aortic valve replacement (TAVR) (n=431). Elevated plasma concentrations of TNF-α vs. Lower plasma concentrations of TNF-α was evaluated on 12-month mortality (HR 1.003, 95% CI 1.001-1.005, p=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: